Maxim Group Lowers Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00

Silexion Therapeutics (NASDAQ:SLXN) had its target price dropped by investment analysts at Maxim Group from $9.00 to $5.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Maxim Group’s target price would suggest a potential upside of 329.18% from the stock’s previous close.

Silexion Therapeutics Trading Up 5.0 %

SLXN traded up $0.06 during trading on Thursday, hitting $1.17. 143,521 shares of the stock were exchanged, compared to its average volume of 16,142,936. Silexion Therapeutics has a 1 year low of $0.58 and a 1 year high of $41.85. The firm has a 50 day simple moving average of $1.27 and a 200 day simple moving average of $3.03.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Silexion Therapeutics stock. Wildcat Capital Management LLC purchased a new position in shares of Silexion Therapeutics Corp (NASDAQ:SLXN) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,020,852 shares of the company’s stock, valued at approximately $536,000. Silexion Therapeutics accounts for about 0.3% of Wildcat Capital Management LLC’s portfolio, making the stock its 7th biggest holding. Wildcat Capital Management LLC owned about 7.38% of Silexion Therapeutics at the end of the most recent reporting period. 10.95% of the stock is currently owned by institutional investors and hedge funds.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.